Integrin-linked kinase as a target for ERG-mediated invasive properties in prostate cancer models

Carcinogenesis

Volumn 33, Issue 12, 2012, Pages 2558-2567

  Becker Santos, Daiana D ^a,b   Guo, Yubin ^c   Ghaffari, Mazyar ^b,c   Vickers, Elaine D ^c   Lehman, Melanie ^c   Altamirano Dimas, Manuel ^c   Oloumi, Arusha ^a   Furukawa, Junya ^c   Sharma, Manju ^c   Wang, Yuzhuo ^a,b,c   Dedhar, Shoukat ^a,b,c   Cox, Michael E ^b,c  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c VANCOUVER COASTAL HEALTH RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 14; CYTOKERATIN 18; CYTOKERATIN 5; CYTOKERATIN 8; INTEGRIN LINKED KINASE; LYMPHOID ENHANCER FACTOR 1; NERVE CELL ADHESION MOLECULE; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR ZEB1; UVOMORULIN; VIMENTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ERYTHROBLASTOSIS VIRUS E26 ONCOGENE LIKE GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RNA INTERFERENCE;

ANIMALS; AZO COMPOUNDS; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; LYMPHOID ENHANCER-BINDING FACTOR 1; MALE; MICE; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PYRAZOLES; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS;

EID: 84870331018     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs285     Document Type: Article

References (57)

1. Tomlins, S.A. et al. (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science, 310, 644-648.
2. Helgeson, B.E. et al. (2008) Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res., 68, 73-80.
3. Mehra, R. et al. (2007) Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res., 67, 7991-7995.
4. Perner, S. et al. (2006) TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res., 66, 8337-8341.
5. Kumar-Sinha, C. et al. (2008) Recurrent gene fusions in prostate cancer. Nat. Rev. Cancer, 8, 497-511.
6. Tomlins, S.A. et al. (2009) ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur. Urol., 56, 275-286.
7. Petrovics, G. et al. (2005) Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene, 24, 3847-3852.
8. Rajput, A.B. et al. (2007) Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J. Clin. Pathol., 60, 1238-1243.
9. Barry, M. et al. (2007) TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. Urology, 70, 630-633.
10. Nam, R.K. et al. (2007) Expression of TMPRSS2: ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. J. Urol., 177, 467-468.
11. FitzGerald, L.M. et al. (2008) Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer. BMC Cancer, 8, 230.
12. Attard, G. et al.; Transatlantic Prostate Group. (2008) Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene, 27, 253-263.
13. Yoshimoto, M. et al. (2008) Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod. Pathol., 21, 1451-1460.
14. Carver, B.S. et al. (2009) Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat. Genet., 41, 619-624.
15. Markert, E.K. et al. (2011) Molecular classification of prostate cancer using curated expression signatures. Proc. Natl. Acad. Sci. U.S.A., 108, 21276-21281.
16. Seth, A. et al. (2005) ETS transcription factors and their emerging roles in human cancer. Eur. J. Cancer, 41, 2462-2478.
17. Turner, D.P. et al. (2008) ETS transcription factors: oncogenes and tumor suppressor genes as therapeutic targets for prostate cancer. Expert Rev. Anticancer Ther., 8, 33-42.
18. Tomlins, S.A. et al. (2008) Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia, 10, 177-188.
19. Klezovitch, O. et al. (2008) A causal role for ERG in neoplastic transformation of prostate epithelium. Proc. Natl. Acad. Sci. U.S.A., 105, 2105-2110.
20. Hollenhorst, P.C. et al. (2004) Expression profiles frame the promoter specificity dilemma of the ETS family of transcription factors. Nucleic Acids Res., 32, 5693-5702.
21. Sun, C. et al. (2008) TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene, 27, 5348-5353.
22. Hu, Y. et al. (2008) Delineation of TMPRSS2-ERG splice variants in prostate cancer. Clin. Cancer Res., 14, 4719-4725.
23. Gupta, S. et al. (2010) FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res., 70, 6735-6745.
24. Leshem, O. et al. (2011) TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model. PLoS ONE, 6, e21650.
25. Savagner, P. (2001) Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays, 23, 912-923.
26. Kalluri, R. et al. (2009) The basics of epithelial-mesenchymal transition. J. Clin. Invest., 119, 1420-1428.
27. McDonald, P.C. et al. (2008) Integrin-linked kinase-essential roles in physiology and cancer biology. J. Cell. Sci., 121(Pt 19), 3121-3132.
28. McPhee, T.R. et al. (2008) Integrin-linked kinase regulates E-cadherin expression through PARP-1. Dev. Dyn., 237, 2737-2747.
29. Guaita, S. et al. (2002) Snail induction of epithelial to mesenchymal transition in tumor cells is accompanied by MUC1 repression and ZEB1 expression. J. Biol. Chem., 277, 39209-39216.
30. Novak, A. et al. (1998) Cell adhesion and the integrin-linked kinase regulate the LEF-1 and beta-catenin signaling pathways. Proc. Natl. Acad. Sci. U.S.A., 95, 4374-4379.
31. Wang, Y. et al. (2001) A human prostatic epithelial model of hormonal carcinogenesis. Cancer Res., 61, 6064-6072.
32. Fielding, A.B. et al. (2008) Integrin-linked kinase localizes to the centrosome and regulates mitotic spindle organization. J. Cell Biol., 180, 681-689.
33. Lee, G.Y. et al. (2007) Three-dimensional culture models of normal and malignant breast epithelial cells. Nat. Methods, 4, 359-365.
34. Cussenot, O. et al. (1991) Immortalization of human adult normal prostatic epithelial cells by liposomes containing large T-SV40 gene. J. Urol., 146, 881-886.
35. Hayward, S.W. et al. (1995) Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1. In Vitro Cell. Dev. Biol. Anim., 31, 14-24.
36. Bello, D. et al. (1997) Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis, 18, 1215-1223.
37. Thompson, E.W. et al. (2005) Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? Cancer Res., 65, 5991-5995.
38. Veveris-Lowe, T.L. et al. (2005) Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelialmesenchymal transition (EMT)-like effect in prostate cancer cells. Endocr. Relat. Cancer, 12, 631-643.
39. Tan, C. et al. (2001) Inhibition of integrin linked kinase (ILK) suppresses beta-catenin-Lef/Tcf-dependent transcription and expression of the E-cadherin repressor, snail, in APC-/- human colon carcinoma cells. Oncogene, 20, 133-140.
40. Rosanò, L. et al. (2005) Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells. Cancer Res., 65, 11649-11657.
41. Medici, D. et al. (2010) Type I collagen promotes epithelial-mesenchymal transition through ILK-dependent activation of NF-kappaB and LEF-1. Matrix Biol., 29, 161-165.
42. Graff, J.R. et al. (2001) Integrin-linked kinase expression increases with prostate tumor grade. Clin. Cancer Res., 7, 1987-1991.
43. Heebøll, S. et al. (2009) Snail1 is over-expressed in prostate cancer. APMIS, 117, 196-204.
44. Li, Y. et al. (2009) LEF1 in androgen-independent prostate cancer: regulation of androgen receptor expression, prostate cancer growth, and invasion. Cancer Res., 69, 3332-3338.
45. Troussard, A.A. et al. (2006) Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival. Cancer Res., 66, 393-403.
46. Younes, M.N. et al. (2005) Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer. Mol. Cancer Ther., 4, 1146-1156.
47. Attwell, S. et al. (2000) The integrin-linked kinase (ILK) suppresses anoikis. Oncogene, 19, 3811-3815.
48. Hannigan, G.E. et al. (1996) Regulation of cell adhesion and anchoragedependent growth by a new beta 1-integrin-linked protein kinase. Nature, 379, 91-96.
49. Frisch, S.M. et al. (1994) Disruption of epithelial cell-matrix interactions induces apoptosis. J. Cell Biol., 124, 619-626.
50. Kang, Y.S. et al. (2010) Inhibition of integrin-linked kinase blocks podocyte epithelial-mesenchymal transition and ameliorates proteinuria. Kidney Int., 78, 363-373.
51. Demichelis, F. et al. (2007) TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene, 26, 4596-4599.
52. McLaughlin, F. et al. (2001) Combined genomic and antisense analysis reveals that the transcription factor Erg is implicated in endothelial cell differentiation. Blood, 98, 3332-3339.
53. Mehra, R. et al. (2008) Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res., 68, 3584-3590.
54. Fuchs, B.C. et al. (2008) Epithelial-to-mesenchymal transition and integrinlinked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res., 68, 2391-2399.
55. King, J.C. et al. (2009) Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat. Genet., 41, 524-526.
56. Persad, S. et al. (2000) Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc. Natl. Acad. Sci. U.S.A., 97, 3207-3212.
57. Edwards, L.A. et al. (2005) Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth. Oncogene, 24, 3596-3605.